Literature DB >> 9690110

[High frequency current catheter ablation of accessory conduction pathways].

G Hindricks1, H Kottkamp, M Borggrefe, G Breithardt.   

Abstract

Radiofrequency catheter ablation has established as the first line therapy for the curative treatment of patients with accessory pathway. Atrioventricular accessory pathways irrespective of the exact localisation can be successfully ablated in more than 90% of all cases. Severe complications associated with the ablation procedure are rare and occur in approximately 2% of patients treated. The recurrence rate after successful ablation is approximately 8 to 10%. Recurrence of accessory pathway conduction occurs almost exclusively within the first 3 months following successful ablation, late recurrences are rare. Patients with variants of accessory pathways such as atriofascicular pathways or retrogradely conducting accessory pathways with decremental conduction properties can also be cured with a high success rate. Because of its well balanced efficacy-risk profile radiofrequency catheter ablation should be recommended as the first line therapy to all symptomatic patients with accessory pathway.

Entities:  

Mesh:

Year:  1998        PMID: 9690110     DOI: 10.1007/bf03044318

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  42 in total

1.  Diagnosis and cure of the Wolff-Parkinson-White syndrome or paroxysmal supraventricular tachycardias during a single electrophysiologic test.

Authors:  H Calkins; J Sousa; R el-Atassi; S Rosenheck; M de Buitleir; W H Kou; A H Kadish; J J Langberg; F Morady
Journal:  N Engl J Med       Date:  1991-06-06       Impact factor: 91.245

2.  Tissue heating during radiofrequency catheter ablation: a thermodynamic model and observations in isolated perfused and superfused canine right ventricular free wall.

Authors:  D E Haines; D D Watson
Journal:  Pacing Clin Electrophysiol       Date:  1989-06       Impact factor: 1.976

3.  Developments, complications and limitations of catheter-mediated electrical ablation of posterior accessory atrioventricular pathways.

Authors:  G H Bardy; T D Ivey; F Coltorti; R B Stewart; G Johnson; H L Greene
Journal:  Am J Cardiol       Date:  1988-02-01       Impact factor: 2.778

4.  Variants of preexcitation--specialized atriofascicular pathways, nodofascicular pathways, and fasciculoventricular pathways: electrophysiologic findings and target sites for radiofrequency catheter ablation.

Authors:  H Kottkamp; G Hindricks; H Shenasa; X Chen; T Wichter; M Borggrefe; G Breithardt
Journal:  J Cardiovasc Electrophysiol       Date:  1996-10

5.  Radiofrequency current catheter ablation of accessory atrioventricular pathways.

Authors:  K H Kuck; M Schlüter; M Geiger; J Siebels; W Duckeck
Journal:  Lancet       Date:  1991-06-29       Impact factor: 79.321

6.  Recognition and catheter ablation of subepicardial accessory pathways.

Authors:  J J Langberg; K C Man; V R Vorperian; B Williamson; S J Kalbfleisch; S A Strickberger; J D Hummel; F Morady
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

7.  [Guidelines for catheter ablation in patients with tachycardic arrhythmias. German Society of Cardiology--Cardiovascular Research].

Authors: 
Journal:  Z Kardiol       Date:  1994-11

8.  Catheter technique for closed-chest ablation of an accessory atrioventricular pathway.

Authors:  H Weber; L Schmitz
Journal:  N Engl J Med       Date:  1983-03-17       Impact factor: 91.245

9.  Attempted nonsurgical electrical ablation of accessory pathways via the coronary sinus in the Wolff-Parkinson-White syndrome.

Authors:  J D Fisher; R Brodman; S G Kim; J A Matos; L E Brodman; D Wallerson; L E Waspe
Journal:  J Am Coll Cardiol       Date:  1984-10       Impact factor: 24.094

10.  Successful radiofrequency catheter ablation of right sided accessory pathways during sustained atrial fibrillation.

Authors:  G Hindricks; H Kottkamp; X Chen; S Willems; G Breithardt; M Borggrefe
Journal:  Eur Heart J       Date:  1995-07       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.